Nuvalent CEO Porter executes 10b5-1 plan: 27,000 shares sold after option exercise
Rhea-AI Filing Summary
James R. Porter, President and CEO and a director of Nuvalent, Inc. (NUVL), reported multiple transactions on 08/15/2025 under a pre-existing Rule 10b5-1 trading plan adopted April 2, 2024. He acquired 27,000 shares by exercising stock options at an $18.93 exercise price and simultaneously sold 27,000 shares across three blocks (20,035; 6,865; 100) at weighted average prices of approximately $75.22, $75.98, and $76.90, respectively.
Following these transactions his beneficial ownership of Class A common stock decreased from 276,062 to 249,062 shares. The option underlying the 27,000 shares vests per the grant schedule with an expiration date of 01/04/2032. The filing was signed by an attorney-in-fact on 08/19/2025.
Positive
- Transactions were executed pursuant to a Rule 10b5-1 trading plan, increasing compliance transparency
- The filing discloses exercise price ($18.93), sale quantities, and weighted-average prices, providing clear detail
Negative
- Beneficial ownership of Class A common stock declined by 27,000 shares from 276,062 to 249,062, reflecting insider sales
- Sales occurred at prices in the mid-$70s which may be perceived by some investors as management monetizing equity
Insights
TL;DR: Insider exercised options and sold an equal number of shares under a Rule 10b5-1 plan; transaction appears procedural, not a new directional signal.
The filing shows an option exercise at $18.93 for 27,000 shares and concurrent sales of 27,000 shares at weighted-average prices in the mid-$70s, executed under a 10b5-1 plan adopted April 2, 2024. Net beneficial holdings declined from 276,062 to 249,062 shares. For investors, these transactions document liquidity actions by management and the use of a pre-established trading plan that limits contemporaneous interpretation about management's view on valuation. The exercise and sale sizes are modest relative to many institutional holdings but are material to officer-level disclosure requirements.
TL;DR: Use of a documented 10b5-1 plan and attorney-in-fact signature demonstrates compliance and procedural transparency.
The report explicitly states the trades were effected pursuant to a Rule 10b5-1 trading plan, which provides an affirmative defense to insider trading claims when properly adopted and executed. The filing includes vesting details for the exercised option and provides weighted-average sale prices and ranges for multiple transactions. The presence of an attorney-in-fact signature and the explanatory footnotes align with standard disclosure practices for executive transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 27,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 27,000 | $18.93 | $511K |
| Sale | Class A Common Stock | 20,035 | $75.22 | $1.51M |
| Sale | Class A Common Stock | 6,865 | $75.98 | $522K |
| Sale | Class A Common Stock | 100 | $76.90 | $8K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 2, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.67 to $75.66, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.67 to $76.66, inclusive. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
